The Oncology segment focuses on the research, development, and commercialization of innovative therapies for various cancers. Hansoh's R&D efforts in this area include the development of small molecule drugs, monoclonal antibodies, and other targeted therapies. The company is actively involved in clinical trials to evaluate the efficacy and safety of its oncology products. This segment addresses significant unmet medical needs in cancer treatment, aiming to improve patient outcomes and survival rates. Hansoh's market positioning is strengthened by its strategic collaborations and partnerships, such as the one with EQRx for almonertinib. Future opportunities include expanding the oncology pipeline and exploring new treatment modalities like immunotherapy. Regulatory aspects involve obtaining approvals from the NMPA and other regulatory bodies. The company is also focused on expanding its reach in the global oncology market.

This segment is dedicated to the research, development, and commercialization of pharmaceuticals for the treatment of CNS disorders. Hansoh's R&D activities include the discovery and development of novel compounds targeting various neurological and psychiatric conditions. The company utilizes advanced technologies and methodologies in drug discovery, including high-throughput screening and structure-based drug design. The therapeutic areas covered include depression, anxiety, schizophrenia, and other neurological conditions. The patient impact is significant, as these drugs aim to improve the quality of life for individuals suffering from debilitating mental health conditions. Hansoh's market positioning is enhanced by its focus on innovative drug development and strategic collaborations. Future opportunities include expanding the CNS pipeline and exploring new treatment modalities. Regulatory aspects involve obtaining approvals from relevant health authorities. The company is also focused on expanding its reach in the global CNS market.

This segment focuses on the development, manufacturing, and commercialization of drugs for cardiovascular diseases and diabetes. Hansoh's R&D efforts include the development of small molecule drugs and other therapies to treat conditions such as hypertension, hyperlipidemia, and diabetes. The company utilizes advanced technologies and methodologies in drug discovery and development, including clinical trials to evaluate the efficacy and safety of its products. The therapeutic areas covered include cardiovascular diseases and diabetes, addressing significant unmet medical needs. The patient impact is substantial, as these drugs aim to improve the health and well-being of individuals suffering from these chronic conditions. Hansoh's market positioning is strengthened by its focus on innovative drug development and strategic collaborations. Future opportunities include expanding the product pipeline and exploring new treatment modalities. Regulatory aspects involve obtaining approvals from relevant health authorities. The company is also focused on expanding its reach in the global market for cardiovascular and diabetes drugs.

This segment is dedicated to the research, development, and commercialization of pharmaceuticals for the treatment of infectious diseases. Hansoh's R&D activities include the discovery and development of novel compounds targeting various bacterial, viral, and fungal infections. The company utilizes advanced technologies and methodologies in drug discovery, including high-throughput screening and structure-based drug design. The therapeutic areas covered include bacterial infections, viral infections, and fungal infections. The patient impact is significant, as these drugs aim to treat and prevent infectious diseases, improving patient outcomes and reducing the spread of infections. Hansoh's market positioning is enhanced by its focus on innovative drug development and strategic collaborations. Future opportunities include expanding the anti-infectives pipeline and exploring new treatment modalities. Regulatory aspects involve obtaining approvals from relevant health authorities. The company is also focused on expanding its reach in the global anti-infectives market.